|
US4072565A
(en)
|
1974-11-04 |
1978-02-07 |
The Dow Chemical Company |
Production of viruses in tissue culture without use of serum
|
|
USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
|
DE3271210D1
(en)
|
1981-12-24 |
1986-06-19 |
Asahi Chemical Ind |
Method for the cultivation of normal diploid cells and cultivation medium used therefor
|
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
|
FR2543158B1
(fr)
|
1983-03-24 |
1985-11-15 |
Inst Nat Sante Rech Med |
Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
|
|
DE3801236A1
(de)
|
1988-01-18 |
1989-07-27 |
Boehringer Mannheim Gmbh |
Pentosansulfat-medium
|
|
US6048728A
(en)
|
1988-09-23 |
2000-04-11 |
Chiron Corporation |
Cell culture medium for enhanced cell growth, culture longevity, and product expression
|
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
|
US5426699A
(en)
|
1993-10-25 |
1995-06-20 |
Antec Corporation |
Method and apparatus for digitizing a scrambled analog video signal
|
|
EP0666312A1
(en)
|
1994-02-08 |
1995-08-09 |
Wolfgang A. Renner |
Process for the improvement of mammalian cell growth
|
|
US5856179A
(en)
|
1994-03-10 |
1999-01-05 |
Genentech, Inc. |
Polypeptide production in animal cell culture
|
|
US5705364A
(en)
|
1995-06-06 |
1998-01-06 |
Genentech, Inc. |
Mammalian cell culture process
|
|
US6656466B1
(en)
|
1995-06-06 |
2003-12-02 |
Genetech, Inc. |
Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
|
|
JP4306813B2
(ja)
|
1995-09-19 |
2009-08-05 |
アスビオファーマ株式会社 |
動物細胞の新規培養方法
|
|
US6528286B1
(en)
|
1998-05-29 |
2003-03-04 |
Genentech, Inc. |
Mammalian cell culture process for producing glycoproteins
|
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US6924124B1
(en)
|
2002-08-23 |
2005-08-02 |
Immunex Corporation |
Feeding strategies for cell culture
|
|
US7429491B2
(en)
|
2003-05-15 |
2008-09-30 |
Wyeth |
Restricted glucose feed for animal cell culture
|
|
EP1664283A4
(en)
|
2003-09-18 |
2007-12-26 |
Raven Biotechnologies Inc |
CELL CULTURE MEDIA
|
|
TWI384069B
(zh)
|
2004-08-27 |
2013-02-01 |
Pfizer Ireland Pharmaceuticals |
多胜肽之製法
|
|
PL2253644T3
(pl)
|
2005-12-20 |
2014-04-30 |
Bristol Myers Squibb Co |
Kompozycje i sposoby wytwarzania kompozycji
|
|
SI2522717T1
(sl)
|
2006-01-04 |
2014-05-30 |
Baxter International Inc. |
Mediji celične kulture brez oligopeptidov
|
|
NZ587107A
(en)
|
2006-06-02 |
2012-05-25 |
Regeneron Pharma |
High affinity antibodies to human il-6 receptor
|
|
US8911964B2
(en)
*
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
WO2008154014A2
(en)
|
2007-06-11 |
2008-12-18 |
Amgen Inc. |
A method for culturing mammalian cells to improve recombinant protein production
|
|
BRPI0813985B1
(pt)
|
2007-07-31 |
2022-05-10 |
Regeneron Pharmaceuticals, Inc |
Anticorpos humanos ou fragmentos de ligação a antígenos, composição farmacêutica dos mesmos e método para produzir um anticorpo anti-cd20 humana ou fragmento de ligação a antígeno de um anticorpo
|
|
US8309088B2
(en)
|
2007-08-10 |
2012-11-13 |
Regeneron Pharmaceuticals, Inc. |
Method of treating osteoarthritis with an antibody to NGF
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
LT2975051T
(lt)
|
2009-06-26 |
2021-07-12 |
Regeneron Pharmaceuticals, Inc. |
Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
|
JOP20190250A1
(ar)
|
2010-07-14 |
2017-06-16 |
Regeneron Pharma |
صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
|
|
AR083044A1
(es)
|
2010-09-27 |
2013-01-30 |
Regeneron Pharma |
Anticuerpos anti-cd48 y usos de los mismos
|
|
CN106267189B
(zh)
|
2010-10-06 |
2021-02-26 |
瑞泽恩制药公司 |
含有抗白介素-4受体(il-4r)的抗体的稳定制剂
|
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
JO3412B1
(ar)
|
2011-06-17 |
2019-10-20 |
Regeneron Pharma |
أجسام مضادة ل angptl3 واستخداماتها
|
|
JP6177249B2
(ja)
|
2011-11-14 |
2017-08-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
|
|
NZ627859A
(en)
|
2012-01-23 |
2015-09-25 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
|
WO2013158279A1
(en)
*
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
|
TWI641619B
(zh)
|
2012-06-25 |
2018-11-21 |
美商再生元醫藥公司 |
抗－ｅｇｆｒ抗體及其用途
|
|
EP2882778B1
(en)
|
2012-08-13 |
2018-04-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
|
JO3532B1
(ar)
|
2013-03-13 |
2020-07-05 |
Regeneron Pharma |
الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
|
|
TWI659968B
(zh)
|
2013-03-14 |
2019-05-21 |
再生元醫藥公司 |
針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
|
|
KR20150127591A
(ko)
|
2013-03-15 |
2015-11-17 |
리제너론 파아마슈티컬스, 인크. |
Il-33 길항제 및 이의 용도
|
|
AR095196A1
(es)
*
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
TWI641620B
(zh)
|
2013-08-21 |
2018-11-21 |
再生元醫藥公司 |
抗－ｐｒｌｒ抗體及其用途
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
MY178160A
(en)
|
2014-03-11 |
2020-10-06 |
Regeneron Pharma |
Anti-egfrviii antibodies and uses thereof
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
CN106659146B
(zh)
|
2014-05-05 |
2020-06-23 |
再生元制药公司 |
人源化c5和c3动物
|
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
|
BR112017005110A2
(pt)
|
2014-09-16 |
2018-01-23 |
Regeneron Pharma |
anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
|
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
|
TWI870789B
(zh)
*
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
CA3246952A1
(en)
|
2018-03-19 |
2025-10-31 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
JP7682853B2
(ja)
|
2019-08-08 |
2025-05-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
新規抗原結合分子フォーマット
|
|
EP4013797A1
(en)
|
2019-08-15 |
2022-06-22 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules for cell targeting and uses thereof
|
|
CA3157075A1
(en)
|
2019-11-05 |
2021-05-14 |
Regeneron Pharmaceuticals, Inc. |
N-terminal scfv multispecific binding molecules
|